The maker of Tylenol is urging the FDA to reject autism warning requests for the drug”s use in pregnancy
WEDNESDAY, Oct. 22, 2025 (HealthDay News) — The maker of Tylenol is urging U.S. health regulators not to add an autism warning label to it and other pain relievers containing acetaminophen, calling the request “unsupported by the scientific evidence and legally and procedurally improper.”
Kenvue’s response, dated Oct. 17, came after a citizen petition sought new pregnancy warnings for acetaminophen.
The petition, filed by the Informed Consent Action Network, asked the U.S. Food and Drug Administration (FDA) to note a possible link between prenatal exposure and autism or attention-deficit/hyperactivity disorder (ADHD).
The petition piggybacked on recent remarks by President Donald Trump, who said Tylenol might cause autism — a claim many health experts say is not supported by science.
“For over a decade — and as recently as August — FDA has fully evaluated the emerging scientific evidence and repeatedly concluded that the data do not support a causal association between acetaminophen use in pregnancy and neurodevelopmental disorders such as autism,” Kenvue said.
In a letter to doctors, FDA Commissioner Dr. Martin Makary said that while some studies describe an association, “a causal relationship has not been established and there are contrary studies in the scientific literature,” NBC News reported.
Experts say acetaminophen remains the only pain reliever considered safe during pregnancy.
More information
The Mayo Clinic has more on acetaminophen.
SOURCE: NBC News, Oct. 21, 2025
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing
Study IDs Neurobiological Roots of Sensory Over-Responsivity
Organized Sports-Based Interventions Can Improve Gross Motor Skills in Autism
Phelan-McDermid Syndrome More Prevalent Than Previously Estimated
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Genomic Newborn Screening Could ID Cancer Predisposition Syndrome
Subclinical Cardiac Dysfunction Linked to Neurodegeneration in APOE-ε4 Carriers